---
title: "Sino Biopharmaceutical Forms Indonesia Joint Venture With Tempo Scan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293908474.md"
description: "Sino Biopharmaceutical (HK:1177) formed a strategic joint venture with Indonesian group PT Tempo Scan Pacific Tbk to expand access to innovative medicines in Indonesia. The new entity, PT Tempo CTTQ Biopharmaceutical Indonesia, is majority-owned by Sino Biopharmaceutical and will leverage its R&D pipeline alongside Tempo Scan’s manufacturing and distribution network. The partnership aims to strengthen regional positioning in Indonesia's growing pharmaceutical market."
datetime: "2026-07-27T09:11:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293908474.md)
  - [en](https://longbridge.com/en/news/293908474.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293908474.md)
generator: "portal-rs"
---

# Sino Biopharmaceutical Forms Indonesia Joint Venture With Tempo Scan

Sino Biopharmaceutical ( (HK:1177) ) has provided an update.

Sino Biopharmaceutical has formed a strategic joint venture with Indonesian healthcare group PT Tempo Scan Pacific Tbk to expand access to innovative medicines in Indonesia. The new entity, PT Tempo CTTQ Biopharmaceutical Indonesia, will leverage Sino Biopharmaceutical’s R&D and product pipeline alongside Tempo Scan’s nationwide manufacturing, regulatory and distribution platform.

The joint venture, in which Sino Biopharmaceutical holds a 51% stake, will focus on regulatory approvals, clinical trials, market entry and commercialization of specialty pharmaceutical products, with potential for future local manufacturing. By targeting Indonesia’s fast-growing pharmaceutical market, supported by universal healthcare expansion and rising demand for innovative therapies, the partnership aims to strengthen Sino Biopharmaceutical’s regional positioning while improving patient access across the country.

The most recent analyst rating on (HK:1177) stock is a Buy  
 with a HK$7.80 price target.  
 To see the full list of analyst forecasts on Sino Biopharmaceutical stock,  
 see the HK:1177 Stock Forecast page. 

**More about Sino Biopharmaceutical**

Sino Biopharmaceutical Limited is a Cayman Islands-incorporated pharmaceutical group focused on research, development and commercialization of innovative and branded therapies. Its portfolio spans oncology, specialty care and cardio-metabolic treatments, and it is pursuing a broader internationalization strategy targeting high-growth emerging markets, including Southeast Asia.

**YTD Price Performance:** -15.71%

**Average Trading Volume:** 98,182,746

**Technical Sentiment Signal:** Hold

**Current Market Cap:** HK$91.71B

### Related Stocks

- [01177.HK](https://longbridge.com/en/quote/01177.HK.md)

## Related News & Research

- [Sino Biopharm says FDA clears IND for TQB6426 GPC3 ADC trial in advanced tumors](https://longbridge.com/en/news/297915540.md)
- [Sino Biopharm files HKEX next-day return disclosing share buyback for cancellation](https://longbridge.com/en/news/297623543.md)
- [Sino Biopharma licenses HER2 ADC TQB2102 to Cipla for India, South Africa, other emerging markets in deal worth up to USD 123 million](https://longbridge.com/en/news/297502425.md)
- [Sino Biopharm’s Kylo-11 Shows Year-Long Lp(a) Cut in Phase I Trial](https://longbridge.com/en/news/297451097.md)
- [UBS: Most China Biotech Firms' 1H26 Sales Beat Expectations; Global R&D Catalysts Key in 2H26, BeOne Medicines Preferred](https://longbridge.com/en/news/297995031.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**